In conclusion, changes in the number and expression levels of CD90 and EpCAM molecules in CTCs at the early time point of Atezo-Bev therapy correlated with treatment effects and reflected in the long-term prognosis of HCC patients. Here, EPCAM is linked to hepatocellular carcinoma.